|Description||ADPM06 is an emerging non-porphyrin PDT agent which has been specifically designed for therapeutic application. It was demonstrated that ADPM06-PDT was well tolerated in vivo and elicited impressive complete response rates in various models of cancer when a short drug-light interval was applied. ADPM06 as an exciting novel PDT agent has significant potential for further translational development.|
|Synonyms||Azadipyrromethane; ADPM 06; ADPM-06.|
|Current Developer||University College Dublin.|
Azacyclonol, also known as γ-pipradol, is a drug used to diminish hallucinations in psychotic individuals.
VUF10460 is a specific non-imidazole histamine H4 receptor agonist (pKi= 7.46, 8.22 for rat H4 receptor and human H4 receptor respectively) with 50-fold selecti...
Indiplon acts as a high-affinity positive and orally active allosteric modulator of the GABAA receptor (Ki=1.2 nM in rat frontal cortex and Ki=1.7 nM and in cer...
JNK-IN-8 inhibits c-Jun phosphorylation in HeLa and A375 cells with EC50 of 486 nM and 338 nM, respectively.
A potent inhibitor of Cox-2, IDO and NOS II
AZD 9272 is a potent, long-acting and selective nervous system penetrant mGlu5 antagonist with IC50 values of 2.6 and 7.6 nM for rat and human receptors, respec...
GSK-8573 is an inactive control of GSK-2801, which is a potent inhibitor of BAZ2A and BAZ2B bromodomains.
FG 7142 is a benzodiazepine inverse agonist and anxiogenic agent. FG 7142 increases tyrosine hydroxylation and upregulates β-adrenoceptors in mouse cerebral cor...